Monica Casucci is the head of the Innovative Immunotherapies Unit at the IRCCS San Raffaele Scientific Institute (OSR, Milan, IT). Her research interests are focused on CAR T-cell therapy of cancer. During her PhD/postdoc, she developed a new CAR-based strategy targeting CD44v6 and she took part to the development of one of the first animal models recapitulating cytokine release syndrome/neurotoxicity. Now she is involved in the preclinical program on CAR-T cell therapy of cancer at OSR and she participates to different Consortia aimed at promoting the bench-to-bedside translation of CAR-T cell therapies in Italy and in Europe. Main activities of her Research Unit include improvement of CAR T-cell fitness, validation of novel CAR specificities, development of strategies to boost efficacy against solid tumours, and exploitation of preclinical models to profile CAR T-cell performances and toxicity profile.